The global intraocular lens market size was valued at USD 3.27 billion in 2016. Globally increasing incidence of cataract as a result of a large aging demographic segment and rising cases of diabetic retinopathy are driving the intraocular lens market. Soaring cases of blindness, surge in healthcare spending capacity, and growing number of ophthalmologists are also supporting the market.
Monofocal IOLs are viewed as a traditional solution for retinal correction. These lenses have a fixed focus for one distance and are most beneficial for patients with cataract in both eyes. Their adoption is also high since they serve as a low-cost solution.
Premium intraocular lenses include multifocal, toric, and accommodative. Advanced benefits offered by premium lenses include multifocal aperture, improved visualization, elimination of the need for glasses after cataract, and higher precision. These features are boosting their adoption globally despite being relatively more expensive.
North America accounted for the largest revenue share in 2016. Rising adoption of premium IOLs in the U.S. and growing number of patients suffering from cataract are boosting the intraocular lens market. Asia Pacific is expected to exhibit the fastest growth rate over the forecast period. Rise in the geriatric population and increasing diabetic population in developing countries is resulting in greater adoption of cataract and other retinal procedures, thereby boosting the APAC market for intraocular lenses.
However, high costs associated with cataract treatment and poor reimbursement for conventional as well as advanced surgeries are challenging the growth of the market for intraocular lenses. Moreover, post-surgical complications threaten to limit growth.
Key trends:
• Rise in geriatric and diabetic population to continue to support growth
• Monofocal IOLs serve as low-cost solution for retinal correction
• Despite being expensive, premium intraocular lenses have been gaining demand thanks to key benefits offered
Rapidly evolving technologies, rise in government funding, and increasing investments by private entities have changed the dynamics of the healthcare industry. Technical advancement is pushing the demand for solutions for the treatment of presbyopia, macular degeneration in diabetic patients, and other ophthalmic disorders.
Accommodative IOLs are preferred by patients suffering from macular degeneration as they support the eye muscles in focusing on intermediate and distant objects. These lenses are widely used in the treatment of presbyopia and astigmatism.
Toric intraocular lenses are especially beneficial for patients suffering from moderate and high astigmatism. These patients suffer from either hyperopia or myopia or sometimes both. Toric IOLs eliminate the need for incision implants required traditionally during astigmatism surgical procedures.
The need for development of cost-effective and efficient intraocular lenses has been driving research and development activities in this product segment. This is sure to present lucrative opportunities to players in the IOL market.
Hospitals have been reporting maximum cataract and vision repair surgeries in the past and are expected to retain their dominance as an end-use segment in the market for intraocular lenses. Availability of technologically advanced facilities for retinal scans and diagnosis of corneal disorders is propelling its growth.
Critical patients are often referred to as super-specialty ophthalmic clinics. Ambulatory surgery centers have been gaining prominence in the market for intraocular lenses owing to miniaturization of surgical devices and availability of specialty doctors. This will enable the segment to register the fastest growth over the forecast period. Rise in CSR activities has also led to an increase in new hospital outpatient facilities (ambulatory centers), enabling treatment facilities to reach remote areas.
North America dominated the IOL market in 2016 and is expected to retain its lead throughout the forecast period. Rising incidences of cataract and other ophthalmic disorders are propelling the growth of the region. In addition, presence of well-defined regulatory guidelines and reimbursement policies for cataract treatments is boosting revenue generation in the market.
Asia Pacific is expected to exhibit the fastest growth in terms of revenue. Anticipated rise in the diabetic population, coupled with the inclusion of eye care in several national social security systems, is likely to boost the market for intraocular lenses in Asia Pacific.
Patients living with diabetes are more prone to cataract, macular degeneration, and other ophthalmic disorders, resulting in greater need for various types of intraocular lenses. According to the International Diabetes Federation, the western Pacific region accounted for the largest diabetic population of 77 million, while the East Asian region accounted for 59 million. India accounted for 50.8 million and China 43.2 million of the diabetic population in the latter region.
A massive patient pool and expanding healthcare tourism industry are propelling the growth of the IOL market in developing countries like China and India. Moreover, government initiatives to develop and commercialize cost-effective treatment options and collaborative efforts of private and government entities to set up eye care facilities are driving the growth of the market in Asia Pacific.
Key regional facts
• Europe is the second-largest IOL market, driven by rise in aging population
• Increase in presbyopia patients and refractive surgery cases is also contributing to the growth
• Rising patient awareness and high disposable income will continue to benefit the Europe market for intraocular lenses
The global market for intraocular lenses is highly competitive. Key participants include Alcon, Inc. (division of Novartis AG), Johnson & Johnson, Valeant, Carl Zeiss Meditec AG, Rayner, EyeKon Medical, Inc., Lenstec, Inc., HumanOptics AG, STAAR Surgical, HOYA GROUP.
Companies are focusing on surgical advancements for ophthalmic disorders at reasonable costs. Major manufacturers of intraocular lenses are investing in mergers and acquisitions to expand revenue share and diversify product portfolio.
Report Attribute |
Details |
Market size value in 2020 |
USD 4.2 billion |
Revenue forecast in 2025 |
USD 5.54 billion |
Growth Rate |
CAGR of 4.7% from 2017 to 2025 |
Base year for estimation |
2016 |
Historical data |
2014 - 2015 |
Forecast period |
2017 - 2025 |
Quantitative units |
Revenue in USD million and CAGR from 2017 to 2025 |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors and trends |
Segments covered |
Product, end use, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; Germany; Japan; China; Brazil; Mexico; South Africa |
Key companies profiled |
Alcon, Inc. (division of Novartis AG); Johnson & Johnson; Valeant; Carl Zeiss Meditec AG; Rayner; EyeKon Medical, Inc.; Lenstec, Inc.; HumanOptics AG; STAAR Surgical; HOYA GROUP |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global intraocular lens market on the basis of product, end use, and region:
Product Outlook (Revenue, USD Million, 2014 - 2025)
Monofocal IOL
Multifocal IOL
Toric IOL
Accommodative IOL
End-use Outlook (Revenue, USD Million, 2014 - 2025)
Hospitals
Ophthalmic Clinics
Ambulatory Care Centers
Eye Research Institutes
Regional Outlook (Revenue, USD Million, 2014 - 2025)
North America
The U.S.
Canada
Europe
The U.K.
Germany
Asia Pacific
China
Japan
Latin America
Brazil
Mexico
Middle East & Africa
South Africa
b. The global intraocular lens market size was estimated at USD 4.0 billion in 2019 and is expected to reach USD 4.2 billion in 2020.
b. The global intraocular lens market is expected to grow at a compound annual growth rate of 4.7% from 2018 to 2025 to reach USD 5.45 billion by 2025.
b. North America dominated the intraocular lens market with a share of 37.4% in 2019. This is attributable to increasing prevalence of cataract and growing Medicare expenditure to enhance eye care in the region.
b. Some key players operating in the intraocular lens market include Alcon, Inc. (division of Novartis AG), Johnson & Johnson, Valeant, Carl Zeiss Meditec AG, Rayner, EyeKon Medical, Inc., Lenstec, Inc., HumanOptics AG, STAAR Surgical, and HOYA GROUP.
b. Key factors that are driving the market growth include increase in diabetic population and growing incidence of visual impairments.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.